海创药业股份有限公司 2025年年度业绩预告

Core Viewpoint - The company, Haichuang Pharmaceutical, anticipates a reduction in losses for the fiscal year 2025, with projected net losses between 150 million to 125 million yuan, representing a year-on-year decrease in losses of approximately 24.81% to 37.34% [2][6]. Group 1: Performance Forecast - The company expects a total profit loss of 150 million to 125 million yuan for 2025, a reduction in losses compared to the previous year by 49.48 million to 74.48 million yuan [2]. - The projected net profit attributable to the parent company is also expected to be between 150 million to 125 million yuan, with a similar reduction in losses compared to the previous year [2]. - The anticipated operating revenue for 2025 is estimated to be between 19 million to 22 million yuan, with the same range applicable for revenue excluding non-core business income [2]. Group 2: Previous Year Performance - In 2024, the company reported an operating revenue of 366,800 yuan, with a total profit loss of 199.48 million yuan and a net profit loss attributable to the parent company of 199.49 million yuan [4]. Group 3: Reasons for Performance Changes - The approval and market launch of the company's first Class 1 new drug, Deuteroenzalutamide soft capsule, in May 2025 is expected to contribute to increased sales revenue compared to the previous year [5]. - The inclusion of Deuteroenzalutamide soft capsule in the National Medical Insurance Drug List is anticipated to lead to a significant price reduction, affecting revenue projections due to inventory adjustments and changes in marketing strategies [5]. - The company plans to reduce research and development expenses for 2025 to between 105 million to 125 million yuan, a decrease from the previous year [5].